Histology
Invasive Carcinoma
CI-CAN-00001040Explore in graph →
603 active trials9 approved drugs37 evidence items
- NCIt
- C9480
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001040Explore in graph →
Clinical trials
1,812 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00601900 | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer | completed | Phase 3 | 394 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02101788 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | completed | Phase 2 / Phase 3 | 260 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 |
| NCT03274687 | Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer | completed | Phase 3 | 296 | NRG OncologyOTHER | 3 | Jul 9, 2026 | clinicaltrials |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06235099 | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer(Solar-Recur) | completed | Phase 3 | 235 | Curium US LLCINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer(ProVent) | completed | Phase 3 | 532 | DendreonINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 157 | Ferring PharmaceuticalsINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT02620280 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1(NeoTRIPaPDL1) | completed | Phase 3 | 278 | Fondazione MichelangeloOTHER | 7 | Mar 6, 2024 | clinicaltrials |
| NCT01394263 | Study of Histrelin Subdermal Implant in Patients With Prostate Cancer | completed | Phase 3 | 59 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT01697384 | Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer | completed | Phase 3 | 138 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05197257 | 68Ga-PSMA-11 PET in Patients With Prostate Cancer | completed | Phase 3 | 39 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT04914195 | Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer | completed | Phase 3 | 155 | Bharat Serums and Vaccines LimitedINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | completed | Phase 3 | 596 | Tesaro, Inc.INDUSTRY | 15 | Jun 2, 2023 | clinicaltrials |
| NCT02624518 | 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 122 | Andrei IagaruOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT02678351 | 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery | completed | Phase 2 / Phase 3 | 74 | Andrei IagaruOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT02673151 | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | completed | Phase 2 / Phase 3 | 61 | Andrei IagaruOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT01837251 | Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | completed | Phase 3 | 682 | AGO Research GmbHINDUSTRY | 6 | Jul 13, 2021 | clinicaltrials |
| NCT02940262 | Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy | completed | Phase 3 | 1,138 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2021 | clinicaltrials |
| NCT03739684 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer(CONDOR) | completed | Phase 3 | 208 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 14, 2021 | clinicaltrials |
| NCT02818725 | I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations(GETUG-AFU19) | completed | Phase 3 | 133 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT02324088 | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer(PEGASE07) | completed | Phase 3 | 174 | UNICANCEROTHER | 0 | Feb 21, 2021 | clinicaltrials |
| NCT03404648 | Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI | completed | Phase 3 | 19 | Mayo ClinicOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02175212 | Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer(AADLPC) | completed | Phase 3 | 362 | Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00226915 | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | completed | Phase 3 | 637 | Japanese Gynecologic Oncology GroupOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01091636 | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer | completed | Phase 2 / Phase 3 | 184 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01856543 | Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation | completed | Phase 3 | 143 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT00041080 | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 139 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | completed | Phase 3 | 961 | GBG Forschungs GmbHOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01011751 | Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma | completed | Phase 3 | 311 | TakedaINDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00983684 | Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer(TARGIT) | completed | Phase 3 | 3,451 | University College, LondonOTHER | 1 | Dec 5, 2014 | clinicaltrials |
| NCT00850772 | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer(OPEN) | completed | Phase 3 | 109 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Jun 12, 2014 | clinicaltrials |
| NCT00110214 | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 3 | 1,050 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00989131 | Study of Paclitaxel in Patients With Ovarian Cancer | completed | Phase 3 | 789 | Oasmia Pharmaceutical ABINDUSTRY | 16 | Feb 4, 2014 | clinicaltrials |
| NCT00182052 | Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer | completed | Phase 3 | 100 | Massachusetts General HospitalOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT01149174 | Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer(EMDA/PRE-TUR) | completed | Phase 3 | 352 | University of Rome Tor VergataOTHER | 1 | Oct 4, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials